Hygroton

Country: New Zealand

Lingwa: Ingliż

Sors: Medsafe (Medicines Safety Authority)

Ingredjent attiv:

Chlortalidone 25mg;  

Disponibbli minn:

AFT Pharmaceuticals Ltd

INN (Isem Internazzjonali):

Chlortalidone 25 mg

Dożaġġ:

25 mg

Għamla farmaċewtika:

Tablet

Kompożizzjoni:

Active: Chlortalidone 25mg   Excipient: Colloidal silicon dioxide Iron oxide red Iron oxide yellow Lactose monohydrate Magnesium stearate Maize starch Purified talc

Unitajiet fil-pakkett:

Bottle, glass, Ph. Eur. type III 15mL, 50 tablets

Klassi:

Prescription

Tip ta 'preskrizzjoni:

Prescription

Manifatturat minn:

Huntsman Advanced Materials Spain S L

Indikazzjonijiet terapewtiċi:

Arterial hypertension, essential or nephrogenic or isolated systolic, as primary therapy or in combination with other antihypertensive agents. Stable, chronic heart failure of mild to moderate degree (New York Heart Association, NHYA: functional class II or III). - Oedema of specific origin - Oedema due to peripheral (chronic) venous insufficiency; short-term therapy if physical measures prove insufficient. - Fluid retention in premenstrual syndrome only if the gain in weight is the main symptom and is well documented. - Ascites due to cirrhosis of the liver in stable patients under close control. - Oedema due to nephrotic syndrome. - Prophylaxis against recurrent calcium oxalate calculi in patients with idiopathic, normocalcaemic hypercalciuria.

Sommarju tal-prodott:

Package - Contents - Shelf Life: Bottle, glass, Ph. Eur. type III 15mL - 50 tablets - 60 months from date of manufacture stored at or below 30°C - Bottle, plastic, HDPE - 50 tablets - 60 months from date of manufacture stored at or below 30°C

Data ta 'l-awtorizzazzjoni:

1969-12-31

Fuljett ta 'informazzjoni

HYGROTON
CHLORTHALIDONE 25 MG TABLETS
WHAT IS IN THIS LEAFLET
Please read this leaflet carefully before you start taking Hygroton.
This leaflet answers some
common questions about Hygroton.
It does not contain all the available information. It does not take
the place of talking to your
doctor or pharmacist.
All medicines have risks and benefits. Your doctor has weighed the
risks of you using
Hygroton against the benefits they expect it will have for you.
IF YOU HAVE ANY CONCERNS ABOUT THIS MEDICINE, ASK YOUR DOCTOR OR
PHARMACIST. KEEP
THIS LEAFLET WITH THE MEDICINE.
You may need to read it again.
WHAT HYGROTON IS USED FOR
HYGROTON IS USED TO TREAT HIGH BLOOD PRESSURE, ALSO CALLED
HYPERTENSION.
Everyone has blood pressure. This pressure helps to move your blood
around your body.
Your blood pressure may be different at various times of the day,
depending on how busy
you are. You have hypertension (high blood pressure) when your blood
pressure stays
higher than is needed, even when you are calm and relaxed.
There are usually no symptoms of hypertension. The only way of knowing
that you have
it is to have your blood pressure checked on a regular basis. You may
feel fine and have
no symptoms but, if high blood pressure is not treated, it can lead to
serious health
problems. Hygroton helps to lower your blood pressure.
HYGROTON IS ALSO USED TO TREAT FLUID BUILDUP CAUSED BY HEART, LIVER OR
KIDNEY
PROBLEMS.
Hygroton belongs to a group of medicines called diuretics (commonly
called fluid or water
pills). These medicines help to reduce the amount of salt and water in
the body by acting
on the kidneys to increase the flow of urine.
Hygroton is also used to treat fluid retention in premenstrual
syndrome, only if the gain
in weight is the main problem reported.
It can be used alone or in combination with other medicines to treat
your condition.
Hygroton is also used to:

Treat heart failure

Prevent the formation of kidney stones in patients with increased
levels of
calcium in the urine
Ask your doctor if you have any q

Karatteristiċi tal-prodott

NEW ZEALAND DATA SHEET
Page 1 of 12
1 HYGROTON
Chlorthalidone 25 mg tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 25 mg chlorthalidone
3 PHARMACEUTICAL FORM
Hygroton 25 mg tablets are speckled pale orange, round, approximately
7.1 mm diameter,
flat tablets with bevelled edges. The tablets are imprinted CW and a
scoreline on one side and
nothing on the other side. Each tablet contains 25 mg of
chlorthalidone.
4 CLINICAL PARTICULARS
4.1
Therapeutic indications
•
Arterial hypertension, essential or nephrogenic or isolated systolic,
as primary therapy or
in combination with other antihypertensive agents.
•
Stable, chronic heart failure of mild to moderate degree (New York
Heart Association,
NHYA: functional class II or III).
•
Oedema of specific origin.
•
Oedema due to peripheral (chronic) venous insufficiency; short-term
therapy if physical
measures prove insufficient.
•
Fluid retention in premenstrual syndrome only if the gain in weight is
the main symptom
and is well documented.
•
Ascites due to cirrhosis of the liver in stable patients under close
control.
•
Oedema due to nephrotic syndrome.
•
Prophylaxis
against
recurrent
calcium
oxalate
calculi
in
patients
with
idiopathic,
normocalcaemic hypercalciuria.
4.2
Dose and method of administration
As with all diuretics, therapy should be initiated with the lowest
possible dose. This dose
should be titrated according to the individual patient's response to
gain maximum therapeutic
benefit while keeping side effects to a minimum.
A single dose is recommended, either daily or every other day, to be
taken in the morning
with food.
Hypertension
The range of clinically useful doses is 12.5-50 mg/day. Recommended
starting doses are either
12.5 or 25 mg/day, the latter being sufficient to produce the maximum
hypotensive effect in
most patients. For a given dose, the full effect is reached after 3-4
weeks. If the decrease in
NEW ZEALAND DATA SHEET
Page 2 of 12
blood pressure proves inadequate with 25 or 50 mg/day, combined
treatment wi